ROS1 and lung carcinoma: No significant differences were observed in the type of TKI, brain radiotherapy, and immunotherapy; TNM staging of lung cancer at the initial diagnosis; time interval from the initial diagnosis of lung cancer to BM surveillance; EGFR, ALK, and ROS1 mutations; age; hypertension; antithrombogenic agent; and sex of patients.